GlassScriptPhysician profile
Navin Rajagopalan
NPI 1215148234
$5,977.08
in general payments reported to CMS, 2019-2025
28 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $343 · 2021: $633 · 2022: $1,439 · 2023: $926 · 2024: $620 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,992.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,420.26 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Astrazeneca Pharmaceuticals LP | $446.51 | 2021-2025 | Farxiga, Lokelma |
| Cvrx, INC. | $440.94 | 2023-2025 | Barostim Neo System |
| Abiomed | $409.97 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $270.91 | 2025 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $195.40 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $192.90 | 2022-2025 | Verquvo |
| Cardiac Dimensions, INC. | $167.92 | 2023 | |
| Pfizer INC. | $159.73 | 2019-2023 | |
| Bridgebio Pharma, INC. | $146.86 | 2025 | Attruby |
| Boston Scientific Corporation | $142.06 | 2020-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| Lexicon Pharmaceuticals, INC. | $132.66 | 2023-2024 | Inpefa |
| Amgen INC. | $128.26 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $119.17 | 2024 | Camzyos |
| Medtronic, INC. | $113.68 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $96.61 | 2021 | |
| Novartis Pharmaceuticals Corporation | $95.55 | 2019-2025 | |
| Philips North America LLC | $63.10 | 2024 | (9278) Bridge |
| Akcea Therapeutics, INC. | $45.05 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $43.08 | 2019-2020 | |
| Scpharmaceuticals INC. | $37.75 | 2025 | |
| Atricure, INC. | $18.38 | 2019 | |
| Kestra Medical Technology Services, INC. | $17.13 | 2025 | Assure Wcd |
| Daiichi Sankyo INC. | $16.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.94 | 2025 | |
| Inspire Medical Systems, INC. | $14.48 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $13.99 | 2023 | Xarelto |
| Amarin Pharma, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Rajagopalan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.